Toxicities of Receptor Tyrosine Kinase Inhibitors in Cancer Pharmacotherapy: Management with Clinical Pharmacology

E-ISSN： 1875-5453|18|3|186-198

ISSN： 1389-2002

Source： Current Drug Metabolism, Vol.18, Iss.3, 2017-03, pp. : 186-198

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer

By Klempner Samuel J Myers Andrea P Mills Gordon B Westin Shannon N

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 16, 2013-11 ,pp. : 2171-2182

Informa Healthcare

Access to resources Recommend Favorite

Cancer Multitarget Pharmacology in Prostate Tumors: Tyrosine Kinase Inhibitors and Beyond

Current Medicinal Chemistry, Vol. 18, Iss. 19, 2011-06 ,pp. : 2827-2835

Bentham Science Publishers

Access to resources Recommend Favorite

Putting the Brakes on Cancer: Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

Pharmaceutical Innovation, Vol. 12, Iss. 1, 2002-12 ,pp. : 12-15

Adis International

Access to resources Recommend Favorite

Mechanisms of Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-Small-Cell Lung Cancer: Clinical and Molecular Considerations

Current Medicinal Chemistry, Vol. 18, Iss. 11, 2011-04 ,pp. : 1613-1628

Bentham Science Publishers

Access to resources Recommend Favorite

Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials

By Ciardiello Fortunato De Vita Ferdinando Orditura Michele De Placido Sabino Tortora Giampaolo

Expert Opinion on Emerging Drugs, Vol. 8, Iss. 2, 2003-11 ,pp. : 501-514

Informa Healthcare

Access to resources Recommend Favorite